Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Do the Control Cohorts of Phase III Randomized Trials Reflect the Real-World Results of DLBCL Patients?

Prokop Vodicka, Andrea Janikova, David Belada, Heidi Mocikova, Vit Prochazka, Juraj Duras, Katerina Steinerova, Vit Campr, Katerina Benesova, Samuel Hricko, Alice Sykorova, Petra Blahovcova, Radek Jaksa, Magdalena Klanova, Marek Trněný

Blood (2023) 142 (Supplement 1): 4485.

https://doi.org/10.1182/blood-2023-185620

Published: 2023

Journal Articles

Role of Angiogenesis and Anti-Angiogenic Treatment Strategies in Mantle Cell Lymphoma

Petra Vockova, MD, Magdalena Klanova, MD PhD, Jan Molinsky, MD PhD, Diana Tuskova, MD, Bokang Calvin Maswabi, MD PhD, Radek Jaksa, MD, Marek Trneny, MD CSc, Pavel Klener, Jr.

Blood (2018) 132 (Supplement 1): 1672.

https://doi.org/10.1182/blood-2018-99-116874

Published: 2018

Journal Articles

MCL1 Targeting Agent Homoharringtonine Exerts Strong Cytotoxicity Towards Diffuse Large B-Cell Lymphoma (DLBCL) Cells and Synergizes with BCL2 Targeting Agent ABT199 in Eliminating BCL2-Positive DLBCL Cells

Magdalena Klanova, MD, Ladislav Andera, M.Sc. PhD, Jan Soukup, MDPhD, Brazina Jan, M.Sc., Jan Svadlenka, M.Sc., Simona Benesova, M.Sc., Dana Prukova, M.Sc. PhD, Dana Vejmelkova, M.Sc., Radek Jaksa, MD, Karel Helman, PhD, Petra Vockova, MD, Lucie Lateckova, MD, Jan Molinsky, MD PhD, Bokang Maswabi, MD, Mahmudul Alam, PhD, Roman Kodet, Prof. MD, Marek Trneny, Pavel Klener, MD, PhD

Blood (2014) 124 (21): 3645.

https://doi.org/10.1182/blood.V124.21.3645.3645

Published: 2014

Journal Articles

The Outcome of Mantle Cell Lymphoma patients after Treatment Failure and Prognostic value of Secondary Mantle Cell International Prognostic Index (sec MIPI)

Marek Trneny, MD, Pavel Klener, MD, David Belada, MD, Heidi Mocikova, MD, PhD, Vit Prochazka, MD, Samuel Vokurka, MD PhD, Jan Pirnos, MD, Katerina Kubackova, MD, Juraj Duras, MD, Jana Salkova, MD, David Salek, MD, Robert Pytlik, MD, PhD, Lucie Barsova, MD, Petr Kessler, MD, Ludmila Boudova, MD, Vit Campr, MD, PhD, Radek Jaksa, MD, Jitka Dlouha, Katerina Benesova, MD

Blood (2014) 124 (21): 4425.

https://doi.org/10.1182/blood.V124.21.4425.4425

Published: 2014

Journal Articles

Immunomodulatory Agent Lenalidomide Enhances Antitumor Functions of Chimeric Receptor-Modified T Cells in Vitro and in Vivo

Otáhal Pavel, MD PhD, Dana Prukova, PhD, Vlastimil Král, PhD, Radek Jaksa, MD, Lucie Lateckova, MD, Petra Vockova, MD, Barbora Svobodova, Marek Trneny, MD, PhD, Prof., Pavel Klener, MD, PhD

Blood (2014) 124 (21): 805.

https://doi.org/10.1182/blood.V124.21.805.805

Published: 2014

Journal Articles

CD200 Expression Improves Differential Diagnosis Between Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Martin Spacek, MD, PhD, Josef Karban, MD, Martin Radek, Eva Babunkova, Jan Kvasnicka, Prof., MD PhD, Radek Jaksa, MD, Adela Berkova, MD, Pavel Klener, MD PhD, Marek Trneny

Blood (2014) 124 (21): 5637.

https://doi.org/10.1182/blood.V124.21.5637.5637

Published: 2014

Journal Articles

Hematopoietic Stem and Progenitor Cells in Patients with Mature B-Cell Malignancies Are Quantitatively and Qualitatively Deregulated Compared to Healthy Controls

Bokang Maswabi, MD, Dana Prukova, PhD, Jan Molinsky, MD PhD, Magdalena Klanova, MD, Lucie Lateckova, MD, Petra Vockova, MD, Tomas Zikmund, MSc, Filipp Savvulidi, MSc, Mahmudul Alam, PhD, Dana Vejmelkova, PhD, Radek Jaksa, MD, Ludek Sefc, PhD, Martin Vokurka, MD PhD, Marek Trneny, Pavel Klener, MD PhD

Blood (2014) 124 (21): 4307.

https://doi.org/10.1182/blood.V124.21.4307.4307

Published: 2014

Journal Articles

Observational Study Alternating R-CHOP21 and R-Cytarabine (3+3 Cycles) for Patients with Newly Diagnosed Mantle Cell Lymphoma Not Eligible for High-Dose Therapy: A Czech Lymphoma Study Group Trial Preliminary Results

Pavel Klener, MD, PhD, Eva Fronkova, MD, PhD, Robert Pytlik, MD, PhD, Marketa Kalinova, D.Sc., PhD, Kristina Forsterova, D.Sc., PhD, David Belada, MD, Martin Simkovic, MD, David Salek, MD, PhD, Heidi Mocikova, MD, PhD, Vit Prochazka, MD, PhD, Vit Campr, MD, PhD, Radek Jaksa, MD, Jozef Kubinyi, MD, PhD, Jiri Dolezal, MD, PhD, Ass.Prof., Jan Trka, MD, PhD, Prof., Marek Trneny, MD, PhD, Prof.

Blood (2014) 124 (21): 1720.

https://doi.org/10.1182/blood.V124.21.1720.1720

Published: 2014

NARROW

Do the Control Cohorts of Phase III Randomized Trials Reflect the Real-World Results of DLBCL Patients?

Role of Angiogenesis and Anti-Angiogenic Treatment Strategies in Mantle Cell Lymphoma

MCL1 Targeting Agent Homoharringtonine Exerts Strong Cytotoxicity Towards Diffuse Large B-Cell Lymphoma (DLBCL) Cells and Synergizes with BCL2 Targeting Agent ABT199 in Eliminating BCL2-Positive DLBCL Cells

The Outcome of Mantle Cell Lymphoma patients after Treatment Failure and Prognostic value of Secondary Mantle Cell International Prognostic Index (sec MIPI)

Immunomodulatory Agent Lenalidomide Enhances Antitumor Functions of Chimeric Receptor-Modified T Cells in Vitro and in Vivo

CD200 Expression Improves Differential Diagnosis Between Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Hematopoietic Stem and Progenitor Cells in Patients with Mature B-Cell Malignancies Are Quantitatively and Qualitatively Deregulated Compared to Healthy Controls

Observational Study Alternating R-CHOP21 and R-Cytarabine (3+3 Cycles) for Patients with Newly Diagnosed Mantle Cell Lymphoma Not Eligible for High-Dose Therapy: A Czech Lymphoma Study Group Trial Preliminary Results

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only